StockUS listing USRNAZNASDAQHealthcareCapital Destroyer

Transcode Therapeutics Inc(RNAZ) Stock Analysis | Healthcare

USD --+0.00%
Reward38Moderate
Risk59Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 20.07M
Reward Ratingⓘ38 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ59 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RNAZ to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Transcode Therapeutics Inc?

, a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers.

AI Brief Pro

The brief on Transcode Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Transcode Therapeutics Inc?

, a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 20.07M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.267
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.